Zhang Xin, Liu Guihong, Peng Xingchen
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
J Clin Med. 2023 Jul 30;12(15):5015. doi: 10.3390/jcm12155015.
Compared to squamous cell carcinoma, head and neck non-squamous cell carcinoma (HNnSCC) is rarer. Integrated survival prediction tools are lacking.
4458 patients of HNnSCC were collected from the SEER database. The endpoints were overall survivals (OSs) and disease-specific survivals (DSSs) of 3 and 5 years. Cases were stratified-randomly divided into the train & validation (70%) and test cohorts (30%). Tenfold cross validation was used in establishment of the model. The performance was evaluated with the test cohort by the receiver operating characteristic, calibration, and decision curves.
The prognostic factors found with multivariate analyses were used to establish the prediction model. The area under the curve (AUC) is 0.866 (95%CI: 0.844-0.888) for 3-year OS, 0.862 (95%CI: 0.842-0.882) for 5-year OS, 0.902 (95%CI: 0.888-0.916) for 3-year DSS, and 0.903 (95%CI: 0.881-0.925) for 5-year DSS. The net benefit of this model is greater than that of the traditional prediction methods. Among predictors, pathology, involved cervical nodes level, and tumor size are found contributing the most variance to the prediction. The model was then deployed online for easy use.
The present study incorporated the clinical, pathological, and therapeutic features comprehensively and established a clinically effective survival prediction model for post-treatment HNnSCC patients.
与鳞状细胞癌相比,头颈部非鳞状细胞癌(HNnSCC)较为罕见。目前缺乏综合生存预测工具。
从监测、流行病学与最终结果(SEER)数据库中收集了4458例HNnSCC患者。终点指标为3年和5年的总生存率(OS)和疾病特异性生存率(DSS)。病例被分层随机分为训练与验证组(70%)和测试组(30%)。在模型建立过程中采用十折交叉验证。通过受试者工作特征曲线、校准曲线和决策曲线对测试组的模型性能进行评估。
多因素分析得出的预后因素被用于建立预测模型。3年总生存率的曲线下面积(AUC)为0.866(95%置信区间:0.844 - 0.888),5年总生存率的AUC为0.862(95%置信区间:0.842 - 0.882),3年疾病特异性生存率的AUC为0.902(95%置信区间:0.888 - 0.916),5年疾病特异性生存率的AUC为0.903(95%置信区间:0.881 - 0.925)。该模型的净效益大于传统预测方法。在预测因素中,病理、受累颈淋巴结水平和肿瘤大小对预测贡献的差异最大。然后将该模型在线部署以便于使用。
本研究综合纳入了临床、病理和治疗特征,为治疗后的HNnSCC患者建立了临床有效的生存预测模型。